Race Oncology Limited (RAC.AX)
AUD 0.98
(-3.92%)
AUD 0.98
(-3.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.91 Million AUD | 66.39% |
| 2023 | 1.15 Million AUD | -18.74% |
| 2022 | 1.41 Million AUD | 170.95% |
| 2021 | 523.1 Thousand AUD | 114.7% |
| 2020 | 243.65 Thousand AUD | 26.82% |
| 2019 | 192.11 Thousand AUD | -37.97% |
| 2018 | 309.7 Thousand AUD | -14.82% |
| 2017 | 363.57 Thousand AUD | -7.16% |
| 2016 | 391.62 Thousand AUD | 229.7% |
| 2015 | 118.78 Thousand AUD | -10.05% |
| 2014 | 132.04 Thousand AUD | 1014.31% |
| 2013 | 11.85 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 1.91 Million AUD | 66.39% |
| 2024 Q2 | 638.75 Thousand AUD | 0.0% |
| 2024 Q4 | 1.91 Million AUD | 0.0% |
| 2023 Q2 | 836.37 Thousand AUD | 0.0% |
| 2023 Q4 | 1.15 Million AUD | 0.0% |
| 2023 FY | 1.15 Million AUD | -18.74% |
| 2022 Q4 | 1.41 Million AUD | 0.0% |
| 2022 Q2 | 785.64 Thousand AUD | 0.0% |
| 2022 FY | 1.41 Million AUD | 170.95% |
| 2021 Q2 | 114.35 Thousand AUD | 0.0% |
| 2021 Q4 | 523.1 Thousand AUD | 0.0% |
| 2021 FY | 523.1 Thousand AUD | 114.7% |
| 2020 Q2 | 221.33 Thousand AUD | 0.0% |
| 2020 FY | 243.65 Thousand AUD | 26.82% |
| 2020 Q4 | 243.65 Thousand AUD | 0.0% |
| 2019 FY | 192.11 Thousand AUD | -37.97% |
| 2019 Q4 | 192.11 Thousand AUD | 0.0% |
| 2019 Q2 | 292.55 Thousand AUD | 0.0% |
| 2018 FY | 309.7 Thousand AUD | -14.82% |
| 2018 Q2 | 166.59 Thousand AUD | 0.0% |
| 2018 Q4 | 309.7 Thousand AUD | 0.0% |
| 2017 Q4 | 363.57 Thousand AUD | 0.0% |
| 2017 FY | 363.57 Thousand AUD | -7.16% |
| 2017 Q2 | 244.94 Thousand AUD | 0.0% |
| 2016 FY | 391.62 Thousand AUD | 229.7% |
| 2016 Q4 | 391.62 Thousand AUD | 0.0% |
| 2016 Q2 | 236.03 Thousand AUD | 0.0% |
| 2015 FY | 118.78 Thousand AUD | -10.05% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | 118.78 Thousand AUD | 0.0% |
| 2015 Q4 | 118.78 Thousand AUD | 0.0% |
| 2014 FY | 132.04 Thousand AUD | 1014.31% |
| 2013 FY | 11.85 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 45.903% |
| Biome Australia Limited | 5.37 Million AUD | 64.334% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 95.711% |
| Biotron Limited | 737.5 Thousand AUD | -159.851% |
| Acrux Limited | 5.68 Million AUD | 66.302% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 64.679% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 48.65% |
| BTC Health Limited | 203.94 Thousand AUD | -839.664% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 85.032% |
| CSL Limited | 27.88 Billion AUD | 99.993% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 76.999% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 93.183% |
| Immutep Limited | 10.97 Million AUD | 82.546% |
| Memphasys Limited | 5.59 Million AUD | 65.732% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 95.518% |
| Noxopharm Limited | 1.28 Million AUD | -48.72% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 17.593% |
| Starpharma Holdings Limited | 8.69 Million AUD | 77.967% |
| Tissue Repair Ltd | 1.35 Million AUD | -41.862% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 54.685% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -524.55% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -420.137% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 79.518% |
| Patrys Limited | 691.36 Thousand AUD | -177.194% |
| Orthocell Limited | 22.08 Million AUD | 91.322% |
| Imugene Limited | 33.14 Million AUD | 94.218% |
| PYC Therapeutics Limited | 10.18 Million AUD | 81.182% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -17.867% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -63.649% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 6.817% |
| Nanollose Limited | 465.64 Thousand AUD | -311.565% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -343.997% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -2136.646% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 44.075% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -83.281% |
| Nyrada Inc. | 855.63 Thousand AUD | -123.977% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.232% |
| Dimerix Limited | 13.89 Million AUD | 86.206% |
| PharmAust Limited | 896.6 Thousand AUD | -113.742% |
| Hexima Limited | 248.67 Thousand AUD | -670.67% |
| AnteoTech Limited | 4.07 Million AUD | 52.974% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 46.533% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 87.942% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -103.542% |
| Actinogen Medical Limited | 1.61 Million AUD | -18.637% |
| Immuron Limited | 2.84 Million AUD | 32.533% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 21.028% |